To identify candidate resistance mechanisms and potential synergistic combinations with JAK2 inhibitors, we utilized CRISPR-Cas9 screening in combination with ruxolitinib in CMS and WSU-AML. This evidence concerns the gene JAK2 and acute myeloid leukemia.